Showing results (281-290 of 333) with videos related to
Sort By:
Pageof 34
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 18, 2021
HER3 Augmentation via Blockade of EGFR/AKT Signaling Enhances Anticancer Activity of HER3-Targeting Patritumab Deruxtecan in EGFR-Mutated Non-Small Cell Lung CancerKimio Yonesaka, Junko Tanizaki, Osamu Maenishi, et al.Oncology Letters|August 7, 2023
Novel single nucleotide polymorphism biomarkers to predict opioid effects for cancer painYoshihiko Fujita, Hiromichi Matsuoka, Yasutaka Chiba, et al.JTO Clinical and Research Reports|August 2, 2024
Real-World Pharmacokinetics, Effectiveness, and Safety of Atezolizumab in Patients With Unresectable Advanced or Recurrent NSCLC: An Exploratory Study of J-TAILShigehiro Yagishita, Yasushi Goto, Makoto Nishio, et al.International Journal of Clinical Oncology|January 19, 2011
High-dose dexamethasone plus antihistamine prevents colorectal cancer patients treated with modified FOLFOX6 from hypersensitivity reactions induced by oxaliplatinYasuhiro Kidera, Taroh Satoh, Shinya Ueda, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|September 14, 2017
Phase III, Randomized, Placebo-Controlled, Double-Blind Trial of Motesanib (AMG-706) in Combination With Paclitaxel and Carboplatin in East Asian Patients With Advanced Nonsquamous Non-Small-Cell Lung CancerKaoru Kubota, Hiroshige Yoshioka, Fumihiro Oshita, et al.Cells|March 26, 2025
Chromosomal Instability Is Associated with cGAS-STING Activation in EGFR-TKI Refractory Non-Small-Cell Lung CancerKimio Yonesaka, Takashi Kurosaki, Junko Tanizaki, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|January 18, 2019
Randomized Phase II Trial Comparing Site-Specific Treatment Based on Gene Expression Profiling With Carboplatin and Paclitaxel for Patients With Cancer of Unknown Primary SiteHidetoshi Hayashi, Takayasu Kurata, Yuichi Takiguchi, et al.Lung Cancer (Amsterdam, Netherlands)|November 21, 2024
Comprehensive serum biomarker analysis reveals IL-8 changes as the only predictor of the effectiveness of immune checkpoint inhibitors for patients with advanced non-small cell lung cancerHiroaki Akamatsu, Yasuhiro Koh, Makoto Nishio, et al.Journal for Immunotherapy of Cancer|February 19, 2020
Propensity score-weighted analysis of chemotherapy after PD-1 inhibitors versus chemotherapy alone in patients with non-small cell lung cancer (WJOG10217L)Ryoji Kato, Hidetoshi Hayashi, Yasutaka Chiba, et al.JTO Clinical and Research Reports|November 29, 2023
Lack of Association of Plasma Levels of Soluble Programmed Cell Death Protein 1, Programmed Death-Ligand 1, and CTLA-4 With Survival for Stage II to IIIA NSCLC After Complete Resection and Adjuvant ChemotherapyJunko Tanizaki, Hiroaki Kuroda, Toshihide Yokoyama, et al.Pageof 34